Vivo Bio Tech Share Price Falls Nearly 5 Percent on 14 July 2026 as Q1 FY27 Net Profit Declines Sharply Year on Year

The Vivo Bio Tech share price fell nearly 5 percent on 14 July 2026 after the biotechnology services provider’s Q1 FY27 net profit came in sharply lower than the same quarter last year, even though the company returned to profitability after a loss making March quarter. The stock was quoting around Rs 23.98, down Rs 1.21 or 4.80 percent, as of 11:56 AM, after opening at Rs 25.05 and touching an intraday low of Rs 23.68, against a previous close of Rs 25.19.

Click Here – Get Free Investment Predictions

Vivo Bio Tech Q1 FY27 Results: Key Reasons for the Fall

Vivo Bio Tech reported consolidated revenue from operations of Rs 1,427.97 lakh for the quarter ended 30 June 2026, up 14.13 percent year on year from Rs 1,251.16 lakh, a steady top line performance across its pre-clinical research and laboratory animal facility platforms. However, net profit for the quarter came in at just Rs 18.76 lakh, sharply lower than the Rs 133.71 lakh reported in Q1 FY26, a decline the company attributed to a higher depreciation and overhead mix.

This year on year profit compression is the central reason behind today’s weak Vivo Bio Tech share price reaction, even though the result technically marks a recovery from the loss reported in the preceding March quarter. Basic and diluted earnings per share for the quarter came in at Rs 0.08, clawing back into positive territory from a negative Rs 2.52 basic EPS in Q4 FY26.

Vivo Bio Tech Stock Performance Today

Metric	Value
Vivo Bio Tech CMP (11:56 AM)	Rs 23.98
Day Change	-4.80%
Day Range	Rs 23.68 – Rs 25.88
Previous Close	Rs 25.19
Q1 FY27 Net Profit	Rs 18.76 lakh (down from Rs 133.71 lakh YoY)
Q1 FY27 Revenue	Rs 1,427.97 lakh (+14.13% YoY)

Check SEBI Registered Investment Advisor Research on Univest

Why Vivo Bio Tech Share Price Gave Back Initial Gains

Interestingly, the Vivo Bio Tech share price had initially risen on 13 July after the results were announced, closing that session up from Rs 23.57 to Rs 25.19. However, as the market had more time to digest the sharp year on year profit decline against steady revenue growth, the stock reversed course on 14 July, giving back the prior session’s gains and more. Total consolidated expenses for the quarter rose to Rs 1,399.65 lakh, with employee costs remaining the largest single expense line at Rs 472.98 lakh, pointing to elevated overheads as a key drag on margins.

What This Means for Vivo Bio Tech Investors

The gap between steady revenue growth and a sharply lower year on year profit highlights margin pressure as the central theme investors should track in the Vivo Bio Tech share price going forward. Since the company operates in the specialised pre-clinical research and laboratory animal facility space, cost discipline around employee and overhead expenses will likely remain the key swing factor for profitability in coming quarters.

Conclusion

The Vivo Bio Tech share price fell on 14 July 2026 as investors focused on the sharp year on year decline in Q1 FY27 net profit despite steady 14 percent revenue growth and a return to profitability after the prior quarter’s loss. Investors should track the company’s cost structure and margin trends closely in the coming quarters.

Download the Univest iOS App or Univest Android App to track Vivo Bio Tech share price live and get quarterly results updates.

Frequently Asked Questions

Why did the Vivo Bio Tech share price fall on 14 July 2026?

Ans. The Vivo Bio Tech share price fell nearly 5 percent as investors focused on Q1 FY27 net profit declining sharply year on year to Rs 18.76 lakh from Rs 133.71 lakh, even though quarterly revenue grew 14.13 percent.

What were Vivo Bio Tech’s Q1 FY27 results?

Ans. Vivo Bio Tech reported consolidated revenue of Rs 1,427.97 lakh, up 14.13 percent year on year, and net profit of Rs 18.76 lakh, down sharply from Rs 133.71 lakh in the same quarter last year.

What was the Vivo Bio Tech share price today?

Ans. Vivo Bio Tech was quoting around Rs 23.98, down about 4.80 percent, as of 11:56 AM on 14 July 2026, after touching an intraday low of Rs 23.68 and a high of Rs 25.88.

Did Vivo Bio Tech return to profit in Q1 FY27?

Ans. Yes, Vivo Bio Tech returned to profitability in Q1 FY27 with earnings per share of Rs 0.08, recovering from a negative basic EPS of Rs 2.52 in the preceding March quarter, though profit remained well below the year ago period.

Why did the Vivo Bio Tech share price initially rise before falling today?

Ans. The Vivo Bio Tech share price initially rose on 13 July after the results were announced, but reversed on 14 July as the market focused more closely on the sharp year on year profit decline despite steady revenue growth.

Should I buy Vivo Bio Tech shares after these Q1 results?

Ans. Investors should consult a SEBI-registered advisor and closely track the company’s cost structure and margin trends before making any investment decision, given the wide gap between revenue growth and profit performance this quarter.